A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 04 Oct 2019 Planned End Date changed from 18 Sep 2019 to 18 Dec 2019.
- 12 Aug 2019 Planned End Date changed from 18 Jul 2018 to 18 Sep 2019.
- 31 Aug 2018 Biomarkers information updated